Predictors of Very Late Events After Percutaneous Mitral Valvuloplasty in Patients With Mitral Stenosis

2016 ◽  
Vol 117 (12) ◽  
pp. 1978-1984 ◽  
Author(s):  
Elisabete Jorge ◽  
Manuel Pan ◽  
Rui Baptista ◽  
Miguel Romero ◽  
Soledad Ojeda ◽  
...  
2001 ◽  
Vol 37 (3) ◽  
pp. 900-903 ◽  
Author(s):  
José A.M de Souza ◽  
Eulogio E Martinez ◽  
John A Ambrose ◽  
Claudia M.R Alves ◽  
Daniel Born ◽  
...  

1991 ◽  
Vol 21 (1) ◽  
pp. 24
Author(s):  
Yang Soo Jang ◽  
Seung Yun Cho ◽  
Nam Sik Chung ◽  
Han Soo Kim ◽  
Sung Oh Whang ◽  
...  

Author(s):  
Benjamin Beska ◽  
Christopher Eggett ◽  
Vijay Kunadian

Author(s):  
Alec Vahanian ◽  
Dominique Himbert ◽  
Eric Brochet ◽  
Grégory Ducrocq ◽  
Bernard Iung

Although the prevalence of rheumatic fever has greatly decreased in Western countries, mitral stenosis (MS) still results in significant morbidity and mortality worldwide. The treatment of MS has been revolutionized since the development of balloon mitral valvuloplasty (BMV). Until the first publication by Inoue in 1984, surgery was the only treatment for patients with mitral stenosis. Since then, the technique has evolved considerably. A large number of patients with varied conditions have now been treated worldwide, enabling us to assess the efficacy and risk of the technique, and long-term results make us better able to select the most appropriate candidates for treatment using this method.


Sign in / Sign up

Export Citation Format

Share Document